DGAP-News: STRATEC - Growth continues in 2011
(firmenpresse) - DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC - Growth continues in 2011
03.05.2011 / 07:45
---------------------------------------------------------------------
STRATEC - Growth continues in 2011
- Sales of EUR 22.2 million in Q1/2011
(+9.5%; Q1/2010: EUR 20.2 million)
- Significantly higher EBIT margin of 18.0% in Q1/2011,
as against 14.8% in Q4/2010 (Q1/2010: 18.5%)
- Consolidated net income of EUR 3.0 million in Q1/2011
(+3.5%; Q1/2010: EUR 2.9 million)
- Dividend of EUR 0.50 distributed
(total distribution sum: EUR 5.8 million)
- Renaming as STRATEC Biomedical AG
Birkenfeld, May 3, 2011
Upon the publication of its interim report as of March 31, 2011, STRATEC
Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today announced its
figures for the period from January 1, 2011 to March 31, 2011.
Key figures (EUR 000s) 01.01.- 03.31.2011 01.01.- 03.31.2010 ChangeFinancial performance
Sales 22,145 20,225 +9.5%
Overall performance 25,368 23,229 +9.2%
EBITDA 4,757 4,433 +7.3%
EBIT 3,982 3,743 +6.4%
Consolidated net income 2,974 2,873 +3.5%
Earnings per share (EUR) 0.26 0.25 +4.0%
EBIT margin (%) 18.0% 18.5%
Sales for the first quarter of 2011 rose by 9.5% from EUR 20.2 million to
EUR 22.1 million, with substantial growth in the consumables business
compared with the fourth quarter of 2010. As a result, the EBIT margin was
increased to 18.0%. The share of sales generated with consumables has
normalized once again, especially when compared with the fourth quarter of
2010, which was affected by several one-off factors and which resulted in
an EBIT margin of 14.8%. Both sales and the EBIT margin are therefore
within the planned corridor forecasted in the financial guidance published
in March 2011, according to which STRATEC expects to generate sales in a
range of between EUR 110 million and EUR 123 million with an EBIT margin of
at least 18.5% in 2011.
Project development
The systems newly launched onto the market in the past year have shown a
promising performance at the beginning of the new year and form the
cornerstone for the growth expected in the second half of the year.
Furthermore, in the coming weeks and months we will be creating production
capacities for further systems currently in preparation for serial
production and expanded production volumes.
Further development projects are progressing on schedule and give reason to
expect further system market launches in the coming years.
Of the new contracts expected in 2011, a first development and supply
contract has already been signed. Further negotiations are in advanced
stages and provide grounds for us to affirm our forecast. Additional
details concerning these contracts will be published once agreements have
been reached with the respective customers.
The subsidiaries STRATEC Biomedical USA (previously Ballista Inc.), STRATEC
Biomedical UK (previously Sanguin), and STRATEC Molecular (previously
Invitek) also concluded new contracts which gives us reason to be
optimistic of winning further contracts within the STRATEC Group. Given
their proportion of consolidated sales, and consistent with customer
wishes, however, these have not been listed individually at this point in
time.
Other developments
The Annual General Meeting held after the end of the first quarter on April
14, 2011 resolved the distribution of a dividend of EUR 0.50 per share. All
other agenda items proposed by the management were also approved.
Accordingly, the company has also been renamed from STRATEC Biomedical
Systems AG to STRATEC Biomedical AG. This renaming should be viewed in
connection with the standardization of the company's structure and the
increased brand recognition of the STRATEC Group. As part of this process,
the subsidiaries have also changed their names. Sanguin International Ltd.
has thus become STRATEC Biomedical UK, Ltd., Invitek Gesellschaft für
Biotechnik&Biodesign mbH has become STRATEC Molecular GmbH, Ballista,
Inc. has become STRATEC Biomedical USA, Inc., and Robion AG has become
STRATEC Biomedical Switzerland AG.
Personnel development
Including temporary employees, the STRATEC Group had a total workforce of
454 employees as of March 31, 2011 (March 31, 2010: 387). Compared with
December 31, 2010, the workforce has therefore increased by a further 14
employees.
Outlook
STRATEC continues to expect further sales growth, accompanied by a rising
EBIT margin, in the 2011 financial year. Specifically, the company expects
to generate sales in a range of EUR 110 million to EUR 123 million in 2011.
Based on sales in the 2010 financial year, the Group expects to achieve
average sales growth (CAGR) of at least 17.0% in the financial years 2011
to 2013. Consistent with these expectations, the EBIT margin should amount
to at least 18.5% in 2011 and to at least 19.0% in the two subsequent
years.
Achievement or any potential exceeding of the upper end of the sales
corridor of EUR 123 million in 2011 is dependent on the timing of the
planned pending market launches of new systems and the approvals in the
relevant markets.
Further details can be found in our Interim Report as of March 31, 2011
published at www.stratec.com> Investor Relations> IR News>
Financial
Reports.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated systems for its partners in the fields of clinical diagnostics
and biotechnology. These partners market such systems, in general together
with their own reagents, to laboratories, blood banks and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical AG as well as subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
03.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49(0)7082 7916 999
E-mail: info(at)stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
122601 03.05.2011
Datum: 03.05.2011 - 07:45 Uhr
Sprache: Deutsch
News-ID 33939
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 127 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC - Growth continues in 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
